Explainer-How the Merck/Moderna cancer vaccine works and possible barriers to wide use
The combination cut recurrence and spread risk versus Keytruda alone, while overall survival data were not yet available, the companies said.
- Moderna and New Jersey's Merck announced on Tuesday that their personalized mRNA cancer vaccine, intismeran autogene, succeeded in a late-stage Phase 3 trial for surgically removed melanoma.
- The personalized treatment requires sequencing a patient's tumor to identify up to 34 unique protein flags, or neoantigens, before manufacturing a custom vaccine designed to spark an immune attack.
- Involving over 1,000 participants whose tumors were surgically removed, the trial marks the first time a cancer vaccine has succeeded in late-stage testing, combining the mRNA therapy with Keytruda.
- Moderna stock surged 11% to $154.15 on Tuesday, adding nearly $45 billion to the company's market value, while rival BioNTech saw a more modest 2% gain during the session.
- William Blair's Myles Minter projected the company could eventually earn $5.4 billion in peak annual sales, as Moderna continues studying the combination treatment in trials for other cancers.
28 Articles
28 Articles
The Moderna cancer vaccine offers hope — now we must speed up personalized therapies
Nature, Published online: 28 August 2026; doi:10.1038/d41586-026-02680-5A positive trial holds promise for treating people with cancer. More research is needed to get effective vaccines to the clinic.
The scientific breakthroughs against cancer that Trump and RFK Jr. want stopped
Jonathan Cohn on the agony and the ecstasy of cancer research in 2026: This past Wednesday, Moderna and Merck announced positive results from a major clinical trial using a cancer vaccine of the kind Wu and her team had envisioned. The target was melanoma, the deadliest form of skin cancer. Using the vaccine in combination with a common cancer drug—rather than relying on the cancer drug alone—significantly reduced the recurrence of melanoma aft…
A personalized mRNA vaccine after surgery helps the immune system recognize cancer cells and reduces the risk of melanoma recurrence.
Rome, Aug. 24 (Adnkronos Salute) - Italian research has played “a leading role in a result of great international importance” in melanoma research. The Int-National Cancer Institute in Milan, reports a message, is “the center that randomized the largest number of patients in the world in the international phase 3 InterPath-001 study: 82 randomized patients out of 128 screened, more than 30 randomized patients more than the second Australian Cent…
The mRNA vaccine of two US companies is a tumor therapy, as it has never existed before. However, it is not a victory over cancer. Then how can the worldwide excitement be explained?
Merck and Moderna announce a breakthrough in developing a personalized vaccine against aggressive skin cancer, melanoma. A study of more than a thousand patients found that the vaccine, combined with immunotherapy, significantly reduced the risk of the disease returning and spreading. Melanoma accounts for only a small proportion of all skin cancer cases, but it is responsible for the majority of deaths from the disease. The new vaccine is uniqu…
Coverage Details
Bias Distribution
- 47% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
